t(1;9)(p34;q34)/SFPQ-ABL1 Fusion in a Patient with Ph-Like Common B-Cell Acute Lymphoblastic Leukemia
Guangying Sheng,Z. Zeng,Jinlan Pan,Qinrong Wang,H. Yao,Lijun Wen,Liang Ma,Depei Wu,Suning Chen
DOI: https://doi.org/10.1159/000452265
2016-11-29
Acta Haematologica
Abstract:ficial lymph nodes. Peripheral blood counting showed a WBC count of 26 × 10 9 /L (47% blasts), a PLT count of 16 × 10 9 /L, and a Hb level of 8.4 g/dL. Bone marrow aspirates showed marked hypercellularity and 72.5% blasts, but no Auer body. Immu nophenotyping using flow cytometry revealed that 67.8% of blasts were positive for cCD79a, CD19, and CD10, but myeloid antigen testing (CD13, CD14, CD15, CD33, CD117, CD35, and c-MPO) was negative. On the basis of the EGIL (European Group of Immunological Markers for Leukemias) scoring system, a diagnosis of common BCP-ALL was made. The cytogenetic analysis showed a kar yotype of 46,XX,t(1; 9) (p34;q34). Reverse-transcription polymerase chain reaction (RT-PCR) for the BCR-ABL1 transcript was negative. In addition, IKZF1 deletion was not found by common PCR and capillary electrophoresis. After two courses of VDP induction chemotherapy containing vindesine, daunorubicin, and prednisone, the patient achieved CR with 1.5% blasts in bone marrow. Unfortunately, the patient relapsed with 55% blasts in bone marrow in February 2014. Then CIOLP regimen consisting of cyclophosphamide, idarubicin, pegaspargaThe ABL1 gene has been mapped on chromosome 9q34, which encodes a cytoplasmic and nuclear protein tyrosine kinase. Since the first report of ABL1 fusion to BCR in the (9; 22) translocation, several uncommon partner genes were identified in various hematological malignancies, such as ETV6, NUP214, EML1 [1] , ZMIZ1 [2] , and RCSD1 [3] respectively. Similar to BCR-ABL, most other ABL1 fusions resulted in dysregulation of ABL signaling pathways. They are considered as Ph-like leukemia characterized by a gene expression profile similar to that of BCR-ABL+ or Ph+ leukemia but lacking BCR-ABL fusion and alterations in lymphoid transcription factor genes (e.g. IKZF1), and have a poor prognosis [4, 5] . Importantly, Ph-like leukemia proved to be responsive to tyrosine kinase inhibitors (TKIs) in some preclinical studies and clinical experience [6, 7] . Recently, SFPQ was described as a new partner gene of ABL1. Up to date, only 3 cases with the SFPQ-ABL1 fusion have been reported in previous studies [8, 9] . We here report the 4th case of Phlike common B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) with the SFPQ-ABL1 fusion resulting from translocation t(1; 9)(p34;q34). A 34-year-old woman was hospitalized in our medical center because of weakness and mild fever in November 2013. Physical examination revealed multiple and superReceived: July 7, 2016 Accepted after revision: October 2, 2016 Published online: November 29, 2016